Biophytis SA
ALBPS
Company Profile
Business description
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
Contact
BC 9, Batiment A 4eme etage
4 pace Jussieu
Sorbonne University
Paris75005
FRAT: +33 144272300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
AI stocks post big gains in Q3. These are the winners and losers
Alphabet and Teradyne post big gains, while Salesforce and Adobe were down in the quarter.
stocks
12 picks for an income portfolio - Q3 2025 update
Fifteen months in and passive income growth has exceeded my target.
stocks
ASX’s only dividend aristocrat reports
Cyclical headwinds persist but loan book and industrial property prop up earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,280.00 | 38.90 | -0.42% |
| CAC 40 | 7,971.78 | 109.76 | -1.36% |
| DAX 40 | 24,378.29 | 0.51 | -0.00% |
| Dow JONES (US) | 46,694.97 | 63.31 | -0.14% |
| FTSE 100 | 9,479.14 | 12.11 | -0.13% |
| HKSE | 26,957.77 | 183.15 | -0.67% |
| NASDAQ | 22,941.67 | 161.16 | 0.71% |
| Nikkei 225 | 47,944.76 | 2,175.26 | 4.75% |
| NZX 50 Index | 13,489.24 | 24.85 | -0.18% |
| S&P 500 | 6,740.28 | 24.49 | 0.36% |
| S&P/ASX 200 | 8,981.40 | 34.80 | -0.39% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |